Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

REC 0/0559 Collirio per il trattamento della cheratite neurotrofica moderata e grave nei pazienti adulti

14 settembre 2026 aggiornato da: RECORDATI GROUP

Efficacia, sicurezza e farmacocinetica di 3 dosi di collirio REC 0/0559 per il trattamento della cheratite neurotrofica di stadio 2 (moderato) e 3 (grave) in pazienti adulti

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This was a Phase 2, international, multicentre, dose-ranging, double-masked, randomised, parallel-group, vehicle-controlled study designed to evaluate 3 different doses of REC 0/0559 vs vehicle in patients with Stage 2 and Stage 3 neurotrophic keratitis (NK).

Tipo di studio

Interventistico

Iscrizione (Effettivo)

108

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Dijon, Francia, 21000
        • Dijon University Hospital CHU Dijon
      • Paris, Francia
        • Hôpital Fondation Adolphe de Rothschild
      • Paris, Francia, 75014
        • CHU Paris Centre - Hôpital Cochin
      • Paris, Francia
        • Hôpital Universitaire Necker
      • Cologne, Germania, 50924
        • Uniklinik Koeln
      • Düsseldorf, Germania, 40225
        • Hospital Eye University of Duesseldorf
      • Frankfurt, Germania, 60590
        • Universitaetsklinikum Frankfurt
      • Homburg, Germania
        • Saarland University Medical Center
      • Mainz, Germania, 55131
        • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
    • Bavaria
      • Munich, Bavaria, Germania, 80336
        • Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik
      • Bari, Italia, 70124
        • Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica
      • Bologna, Italia, 40138
        • DIMES Universit di Bologna
      • Florence, Italia, 50134
        • Azienda Ospedaliero-Universitaria Careggi
      • Forlì, Italia
        • Ospedali Privato
      • Genova, Italia, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Messina, Italia
        • Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
      • Milan, Italia, 20157
        • Ospedale Luigi Sacco
      • Roma, Italia, 00133
        • Fondazione PTV - Policlinico Tor Vergata
    • Calabria
      • Germaneto, Calabria, Italia, 88100
        • Università Magna Grecia di Catanzaro
      • Glasgow, Regno Unito, G75 8RG
        • University Hospital Hairmyres
      • London, Regno Unito
        • Moorfields Eye Hospital NHS Foundation Trust
      • Southampton, Regno Unito, SO16 6YD
        • Southampton General Hospital
    • Mersey
      • Liverpool, Mersey, Regno Unito, L7 8XP
        • Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre
      • Barakaldo, Spagna, 48903
        • Hospital de Cruces
      • Barcelona, Spagna
        • Centro de Oftalmologia Barraquer
      • Barcelona, Spagna, 08035
        • Instituto Microcirugia Ocular IMO
      • Madrid, Spagna, 28040
        • Hospital Clinico San Carlos
      • Seville, Spagna
        • Cartuja Vision - Centro de Servicios Oftlamologicos
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spagna, 33012
        • Instituto Oftalmologico Fernandez-Vega
    • Florida
      • Crystal River, Florida, Stati Uniti, 34429-8722
        • Nature Coast Clinical Research
      • Gainesville, Florida, Stati Uniti, 32605
        • University of Florida
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • University of Maryland School of Medicine UMSOM
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48105
        • University of Michigan - Kellogg Eye Center
    • New York
      • New York, New York, Stati Uniti, 10003
        • Mt. Sinai New York Eye and Ear Infirmary
    • North Carolina
      • Winston-Salem, North Carolina, Stati Uniti, 27157
        • Wake Forest Baptist Medical Center
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37215
        • Toyos Clinic
    • Texas
      • Houston, Texas, Stati Uniti, 77025
        • Houston Eye Associates HEA - Gramercy Location
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53705
        • University of Wisconsin-Madison
      • Budapest, Ungheria
        • Semmelweis University, Dept. of Ophthalmology
      • Pécs, Ungheria
        • University of Pecs - Dpt of Ophthalmology
    • Vas County
      • Szombathely, Vas County, Ungheria, 9700
        • Markusovszky University Teaching Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Have read, understood, and signed the informed consent form (ICF).

  2. Be a male or female aged ≥18 years at the time of ICF signature.

  3. Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.

    for the study eye

  4. Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.

  5. Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.

  6. Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.

Exclusion Criteria:

  1. Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.

  2. Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8

  3. Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.

  4. Have a significant history of alcohol abuse or drug/solvent abuse

  5. Be unwilling to comply with any study assessments or procedures.

  6. Be a woman who is pregnant, nursing or planning a pregnancy.

  7. Be a woman of childbearing potential not using a highly effective method of birth control.

  8. Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.

    For the study eye:

  9. Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.

  10. Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),

  11. Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).

  12. Have severe blepharitis and/or severe meibomian gland disease in the study eye.

  13. Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.

  14. Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.

  15. Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.

  16. Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.

  17. Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.

  18. Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.

  19. Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.

  20. Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.

    For the fellow eye

  21. Have Stage 2 or 3 NK or perforation.

    For any eye:

  22. Have a history of ocular cancer.

  23. Have had prior treatment with Oxervate™

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dose 1 - 0.5 µg/day

Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Altri nomi:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Sperimentale: Dose 2 - 2.5 µg/day

Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Altri nomi:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Sperimentale: Dose 3 - 5 µg/day

Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID

Eye drop solution in single dose unit.

Altri nomi:
  • Rec 0/0559

Eye drop solution with no active substance in single dose unit.

Comparatore placebo: Vehicle

Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID

Eye drop solution with no active substance in single dose unit.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Corneal Healing
Lasso di tempo: At week 8

The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre.

At week 8

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Visual Acuity
Lasso di tempo: At week 8

Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively).

At week 8

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 ottobre 2020

Completamento primario (Effettivo)

29 aprile 2024

Completamento dello studio (Effettivo)

29 aprile 2024

Date di iscrizione allo studio

Primo inviato

17 febbraio 2020

Primo inviato che soddisfa i criteri di controllo qualità

17 febbraio 2020

Primo Inserito (Effettivo)

19 febbraio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • REC0559-B-001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .